Normanno, N. and Gullick, W.J. (2006) Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application? Endocrine-Related Cancer, 13 (1). pp. 3-6. ISSN 1351-0088.
PDF (Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors)
Restricted to Repository staff only
| Contact us about this Publication
The paper by Angelucci et al. published in the current issue of Endocrine-Related Cancer suggests a potential, novel application of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of bone metastases. Interestingly, activity of anti-EGFR agents on the pathogenesis and progression of bone metastases has been described in previous reports, and a number of different mechanisms seem to be involved in this phenomenon. Anti-EGFR agents have a direct activity on tumour cells in which they produce growth inhibition, apoptosis, and reduced invasive capacity through the inhibition of molecules associated with tissue invasion such as urokinase-type plasminogen activator (uPA) and matrix metalloproteinase (MMP)-9. In addition, these compounds have an anti-angiogenic activity, either direct by affecting the proliferation and survival of endothelial cells, or indirect by blocking the production of vascular endothelial growth factor (VEGF) in bone marrow stromal cells and in tumour cells. Finally, EGFR-TKIs can inhibit recruitment of osteoclasts in bone lesions, by affecting the ability of bone marrow stromal cells to induce osteoclast differentiation and activation. Taken together, these findings strongly support prospective clinical trials of anti-EGFR agents in cancer patients with bone metastases in order to define their role in the management of bone disease.
|Uncontrolled keywords:||Antineoplastic Agents/*therapeutic use Bone Neoplasms/metabolism/*prevention & control/secondary Humans Male Prostatic Neoplasms/metabolism/*prevention & control Quinazolines/*therapeutic use Receptor, Epidermal Growth Factor/*antagonists & inhibitors/metabolism Signal Transduction/drug effects|
|Divisions:||Faculties > Science Technology and Medical Studies > School of Biosciences > Biomedical Research Group|
|Depositing User:||Bill Gullick|
|Date Deposited:||30 Aug 2008 19:57|
|Last Modified:||05 Sep 2011 23:34|
|Resource URI:||http://kar.kent.ac.uk/id/eprint/3968 (The current URI for this page, for reference purposes)|
- Depositors only (login required):